
Giving the Immune System a Boost in Cancer With DPP4 Inhibitors
Scientists at Institut Pasteur in France have repurposed DPP4 inhibitors, used to treat type 2 diabetes mellitus, to boost the body's immune response to tumors.
While immuno-oncology agents like the PD-1 and PD-L1 inhibitors have revolutionized cancer care by preventing checkpoint blockade, scientists at the Institut Pasteur have discovered another way to manipulate the body's immune response to a tumor—increased infiltration of T-cells to the tumor site.
In their article published in
Read more on ScienceDaily:
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.